# Selank Withdrawal: What the Research Says About Discontinuation

> Selank withdrawal in the published literature: Russian work emphasizes absence of rebound anxiety after short courses, contrasting Selank with benzodiazepines. Forum reports differ.

## Selank Withdrawal: What the Research Says

Russian short-course studies emphasize the absence of rebound anxiety. Forum reports describe milder mood dips. Long-term human discontinuation data does not exist in the published record.

## Reported discontinuation effects

Selank withdrawal in the published Russian literature is framed by what it does not produce. The principal claim across the trial-era papers is the absence of rebound anxiety following short (7-14 day) intranasal courses [1]. That framing is deliberately positioned against benzodiazepine discontinuation, where rebound anxiety is a known clinical phenomenon. The Zozulia (2008) trial reported a benign acute discontinuation profile across its 14-day arm [1].

Forum and user reports occasionally describe mild mood dips on cessation. These reports are anecdotal, not controlled-trial data, and do not appear in the indexed literature. We document them only because the question is asked frequently enough to warrant a direct answer.

## What the rodent withdrawal models show

The withdrawal story in the rodent literature is not about Selank withdrawal — it is about Selank as an attenuator of withdrawal from other substances. Three published rodent studies document this directly.

Morphine withdrawal: Selank reduced aversive signs of morphine withdrawal in rats, consistent with the molecule's documented opioid-system involvement and naloxone-reversible behavioral profile [12][21].

Alcohol withdrawal: Selank was efficacious during modeling of withdrawal syndrome in rats with stable alcoholic motivation, reducing anxiety- and depression-like behavior in the abstinence phase [13].

Ethanol sensitization: Selank inhibited ethanol-induced hyperlocomotion and blunted the development of behavioral sensitization in DBA/2 mice [14].

These are pharmacological-action studies, not Selank-discontinuation studies. They speak to mechanism, not to what happens when Selank itself stops.

## Long-term discontinuation: what is not known

Long-term human Selank discontinuation data is absent from the published literature. The longest controlled human exposure documented in English-PubMed-indexed sources is the Zozulia (2008) 14-day intranasal course in 62 patients [1]. Beyond that window, controlled human discontinuation data does not exist.

The Russian Federation registration covers short-course pharmacopoeia use. The molecule is not approved for human use in any other jurisdiction. Chronic indefinite Selank exposure is not characterized in the published trial record, and chronic-exposure discontinuation is correspondingly uncharacterized.

That absence is the honest framing. The literature does not document a Selank withdrawal syndrome. It also does not document long-term safety. Both statements are true and neither is reassuring about long-term use.

## Regulatory framing

Selank is registered as a pharmaceutical in the Russian Federation only. It is not approved by the FDA, EMA, MHRA, or TGA. In the United States it is sold strictly as a research chemical. Russian product labeling lists pregnancy and known peptide allergy as contraindications; outside Russia, no regulatory body has issued discontinuation guidance because no regulatory body has approved Selank for human use.


---

A billboard-scale field review of the Russian Selank literature — one trial, twenty rodent studies, zero Western approvals, set in type and signed by no vendor.